Hemay5087
/ Ganzhou Hemay Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 04, 2026
A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1